Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 7/20 | 0.48 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10770736 | 0.83 | NPSR1 (0.61) | F13A1NPSR1MAPTSCDTSHR | |
| SCHEMBL8840822 | 0.79 | F13A1 (0.61) | F13A1MAPTRXFP1LTB4RLMNA | |
| SCHEMBL11286813 | 0.78 | F13A1 (0.56) | F13A1NPSR1MAPTRXFP1LTB4R | |
| SCHEMBL3925297 | 0.78 | F13A1 (0.56) | F13A1NPSR1MAPTRXFP1LTB4R | |
| SCHEMBL10110930 | 0.78 | F13A1 (0.56) | F13A1NPSR1MAPTRXFP1LTB4R | |
| SCHEMBL6207355 | 0.76 | F13A1 (0.53) | F13A1NPSR1MAPTRXFP1LTB4R | |
| SCHEMBL6207760 | 0.76 | TSHR (0.57) | F13A1NPSR1MAPTRXFP1LTB4R | |
| SCHEMBL7794255 | 0.76 | F13A1 (0.58) | F13A1NPSR1MAPTRXFP1LTB4R | |
| SCHEMBL11290737 | 0.76 | F13A1 (0.53) | F13A1NPSR1MAPTRXFP1LTB4R | |
| SCHEMBL7911472 | 0.76 | F13A1 (0.53) | F13A1NPSR1MAPTRXFP1LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585928-B2 | monomers of acetylenic homo- or copolymers; cured polymers has low dielectric constant as insulating layers in microelectronic devices | DOW GLOBAL TECHNOLOGIES (US) | 2009-09-08 | — | — | US | disclosed |
| US-20070027278-A1 | Multifunctional monomers containing bound mesogenic poragen forming moieties and polyarylene compositions therefrom | DOW GLOBAL TECHNOLOGIES LLC | 2007-02-01 | — | — | US | disclosed |
| WO-2005042613-A1 | MULTIFUNCTIONAL MONOMERS CONTAINING BOUND MESOGENIC PORAGEN FORMING MOIETIES AND POLYARYLENE COMPOSITIONS THEREFROM | DOW GLOBAL TECHNOLOGIES INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027278-A1 | Multifunctional monomers containing bound mesogenic poragen forming moieties and polyarylene compositions therefrom | LRBA, CD74, BMP2 | F13A1 21/4885NPSR1 3154/4885MAPT 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.